CapsoVision Inc will release its second quarter 2026 financial results on Thursday, August 13, 2026, after the close of market trading. The announcement marks the next key reporting milestone for the commercial-stage medical technology company, which develops advanced imaging and AI-enabled capsule endoscopy solutions. Investors will gain insight into the company’s operational progress and financial performance during this period, particularly regarding its flagship CapsoCam Plus product and its pipeline development for colon imaging.

The company will host a corresponding conference call and live webcast at 1:30 pm PT / 4:30 pm ET on August 13, 2026, to discuss the results and provide a corporate update. This event allows stakeholders to review the detailed financial data directly from management and ask questions regarding the company’s strategic direction in gastrointestinal disease detection and screening.

Conference Call Details

Investors interested in listening to the conference call may do so by dialing (800) 715-9871 or (646) 307-1963 and referencing conference ID 9178774. The live and archived webcast of the conference call can be found on the Events page in the Investor Relations section of CapsoVision’s website.

About CapsoVision

CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and screening of gastrointestinal diseases. Its flagship product, CapsoCam Plus, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval.

The company’s next pipeline product, CapsoCam Colon with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics.

CapsoVision, Inc. appointed David S. Shields, M.D., to its Board of Directors effective July 1, 2026, as the company advances its AI-enabled capsule endoscopy platform. Dr. Shields, a board-certified gastroenterologist with over 40 years of experience, succeeds Joanne C. Imperial, M.D., who stepped down from the Board but will continue to support the company as an independent clinical consultant.

Dr. Shields has served as a clinical advisor and consultant to CapsoVision for nearly a decade. He maintained a private gastroenterology consulting practice in Palo Alto, California since 1986 and previously served as Assistant Professor of Medicine at Stanford University School of Medicine and Director of Endoscopy at Stanford Hospital. He currently serves as a consultant and clinician at San Mateo County Medical Center and the Palo Alto Veterans Affairs Health Care System.

Strategic Milestones

Johnny Wang, President and Chief Executive Officer of CapsoVision, highlighted the company's upcoming milestones, including the anticipated commercial launch of an AI-assisted reading feature for CapsoCam Plus®. The company is also advancing its second-generation CapsoCam Colon™ program and expects to expand its broader capsule platform.

Board Transition

Dr. Imperial will continue to provide guidance for the pancreatic cancer clinical program and a planned 2027 esophageal varices study. This study will evaluate the next-generation capsule platform incorporating Canon’s advanced imaging technology.